About World Novel Drug Discovery Summit South Korea

행사 소개

Accelerate the Creation of Best-in-Class Platforms for Next-Generation Modalities by Leveraging AI & State-of-the Art Drug Discovery Technologies

South Korea is establishing itself as a distinct drug discovery innovation ecosystem. Fueled by significant government investment and recent partnerships involving companies such as HK Inno.N, Atomatrix, OliX, Galux, Samsung Bioepis, SK Biopharmaceuicals, Dong-A ST and Celltrion, K-Bio is increasingly making headlines through its dedication to integrate AI for smarter, faster and de-risked drug discovery and best-in-class potential platforms.

Built from the ground-up with in-depth market research from senior and expert K-Bio leaders, the World Novel Drug Discovery Summit South Korea is the first forum of its kind bringing together local and international industry leaders to shape Korea’s future as a global drug discovery powerhouse.

Uniting 100+ leaders from Eli Lilly, Sanofi, Hanmi Pharmaceuticals, Portrai, ONCOCROSS, Innovent Biologics and more, this is the unmissable forum for K-Bio and Asian drug discovery enthusiasts to accelerate the development of best-in-class potential platforms and be positioned for global partnership and out licensing opportunities through:

Cutting-edge case studies of biologic and small molecule modality discovery
Development and experimental validation of breakthrough AI/ML platform technologies
International perspectives on proven drug discovery strategies
Collaborative structured and spontaneous networking opportunities

Download the Agenda

Hear from Your 2026 Speakers

전문 연사들의 이야기를 들어보세요

I am thrilled to participate in the World Drug Discovery Summit South Korea. It is a premier platform to discuss how cutting-edge spatial biology is moving beyond basic research to directly solve critical bottlenecks in drug development.

Daeseung Lee, Co-Founder & Chief Executive Officer, Portrai

I am excited to share my perspectives on using AI and multi-omics data to strengthen target identification and credentialing, uncover disease-relevant biology, and support biomarker programs for clinical decision-making. I also look forward to exchanging practical insights with fellow speakers and attendees on translating AI-enabled multi-omics discoveries into meaningful therapeutic and clinical impact.

Daniel Dai, Scientific Manager, Sanofi

I’m really looking forward to the World Drug Discovery Summit South Korea for the opportunity to identify strategic collaborators in drug discovery who can help us broaden our footprint at the intersection of AI and drug discovery.

Shan Chen, Senior Director, AIDD, Innovent Biologics

I’m looking forward to learning how world-leading companies are leveraging AI in drug discovery, particularly in AI-driven target discovery and drug design in the TPD field.

Chunhui Xu, Lead, AI4Glue Platform, Degron Therapeutics

Unmissable Event Highlights

놓칠 수 없는 행사 하이라이트

Global Discovery Leaders Panel Discussion

Hear from Korean and international discovery leaders Eli Lilly, Hanmi Pharm and KIT on the state-of-play of AI/ML in drug discovery, areas of promise and bottlenecks, and strategies to foster global collaborations

Industry-Leading Platform Showcases

Discover insights from leading discovery platform innovators like AIGENDRUG, Degron Tx, Portrai and ONCOCROSS, blending technical and strategic insights with experimental validation to unlock best-in-class discovery

Next-Generation Modality Case Studies

Access modality-agnostic discovery insights with content split evenly across biologics and small molecules including up and comping modalities ADCs, induced proximity and molecular glues, peptides and vaccines

AI/ML De Novo Discovery Workshop

Deep dive into of AI/ML and in silico model training, applications, validation, limitations and iterative DBTL workflows with AIGEN Sciences, Korea University and Seoul National University

Explore the Full Event Guide to Discover:

공식 아젠다를 다운로드하여 다음 내용을 확인하세요

International perspectives to integrate AI/ML technologies to accelerate and enhance drug discovery collaboration opportunities with Eli Lilly, Innovent Bio and Sanofi
Cutting-edge insights to accelerate best-in-class potential platforms from K-Bio trailblazers AIGEN Sciences, Hanmi Pharm, LG Research AI, ONCOCROSS, Portrai and more
Cross-modality case studies with next-generation drug discovery spotlights across ADCs, molecular glues, peptides and cancer vaccines
100+ drug discovery enthusiasts from strategic decision makers to hands-on technical experts across Korean innovators, global pharma leaders and industry-leading service providers
Dedicated structured and spontaneous networking opportunities to foster drug discovery collaborations and partnerships